STUDY QUESTION: Do angiotensin (Ang)-(1-7) levels in human ovarian follicular fluid (FF) correlate with the number and proportion of mature oocytes obtained for IVF?
Introduction
The novel concept of renin-angiotensin system (RAS) includes a complex net of precursors, peptides, enzymes and receptors comprising a systemic (endocrine) and a local paracrine/autocrine system (Ferrario, 2010; Santos et al., 2013) . The main components of the RAS, namely renin, angiotensin-converting enzyme (ACE), angiotensin (Ang) II and its receptors (AT1 and AT2), Ang-(1-7) and its receptor Mas have been demonstrated in the ovaries of different species (Costa et al., 2003; Reis et al., 2011; Viana et al., 2011; Yoshimura, 1997) , where they stimulate steroidogenesis, folliculogenesis, gamete maturation and ovulation (Bumpus et al., 1988; Pena et al., 2010 ; Tonellotto dos Santos et al., 2012) .
Ang-(1-7) is a heptapeptide formed by ACE-independent pathways, whose effects may be distinct, similar or opposite to those of Ang II, depending on the target cell (Santos et al., 2000) . Since the identification of ACE2, an enzyme analog to ACE that is able to generate Ang-(1-7) directly from Ang II or indirectly from Ang I (Donoghue et al., 2000) , and receptor Mas recognition as an endogenous receptor for Ang-(1-7) , the RAS was divided into two axis, one composed by ACE/Ang II/AT1 and another by ACE2/ Ang-(1-7)/Mas.
The expression and functional activity of the RAS in ovarian physiology vary according to the animal species and experimental model. The expression of Mas and ACE2 increased in rat ovaries treated with equine chorionic gonadotropin (Pereira et al., 2009) ; however, Mas expression remained stable during the ovulation process in cattle (Tonellotto dos Santos et al., 2012) . In women, renin and Ang II increased in follicular fluid (FF) during ovulation induction for IVF, which was directly related with the number of ovarian follicles (Itskovitz et al., 1991; Loret de Mola et al., 1999) . In perfused rat and rabbit ovaries, Ang-(1-7) induced an increase in estradiol levels, which was inhibited by A-799, a specific Ang-(1-7) antagonist (Costa et al., 2003; Pereira et al., 2009; Viana et al., 2011) . In cattle, a mono-ovulatory species, FF Ang-(1-7) increased after the preovulatory LH surge, suggesting an involvement of ACE2/Ang-(1-7)/ Mas axis in the ovulation process (Tonellotto dos Santos et al., 2012) . All these results together suggest that ovarian RAS is under gonadotropin control.
The role of ACE2/Ang-(1-7)/Mas axis in human ovary has not been described yet, so in the present study, we sought to evaluate plasma and FF Ang-(1-7) levels and granulosa cell expression of ACE2, ACE and Mas mRNAs in women undergoing controlled ovarian stimulation (COS) for IVF. More specifically, we analyzed the correlations between Ang-(1-7) levels and COS/IVF outcomes, including the number of oocytes collected and the percentage of mature oocytes among them.
Materials and Methods

Ethical approval
The study design, protocol and informed consent form were approved by the local Institutional Review Board and all participants freely signed the informed consent upon enrollment in the study.
Study participants, COS and IVF
Blood and FF samples were collected from 64 women (age 25-42 years) who underwent oocyte retrieval for IVF at the Human Reproduction Laboratory of Federal University of Minas Gerais, from June to December 2012. Patients and cycle characteristics are detailed in Table I . The causes of infertility were male factor (37.5%), tubal obstruction (23.4%), endometriosis (12.5%), male factor + tubal obstruction (9.4%), unexplained infertility (4.7%), tubal obstruction + endometriosis (4.7%), male factor + ovulatory dysfunction (3.1%), male factor + endometriosis (1.6%) and tubal obstruction + ovulatory dysfunction (1.6%). One patient (1.6%) was not infertile but underwent IVF due to partner infection with human immunodeficiency virus. Another group of infertile women (n = 27, median age 36 years) were enrolled at the same institution between August and September 2016 and composed a validation cohort for the granulosa cell mRNA assessment.
COS and collection of follicular aspirates were performed according to the institutional protocol (Rezende et al., 2014) . Briefly, women underwent individualized COS according to age, antral follicular count and basal FSH levels. Pituitary blockade was done with leuprolide acetate or cetrorelix acetate. Ovarian stimulation was performed by recombinant FSH (rFSH) and/or highly purified human urinary gonadotropin at step down doses starting with 225 to 300 IU, followed by ultrasound monitorization. When at least one dominant follicle reached a diameter of 18 mm, recombinant hCG was administered at a dose of 250 μg. Follicles were aspirated 35 h after hCG injection using a 17-gauge follicular aspiration needle connected to a transvaginal probe and a craft suction unit with a negative pressure of 100-200 mmHg. The oocytes were identified in a culture dish using a stereomicroscope. Semen was prepared using the swim-up technique and insemination was performed by conventional IVF or ICSI. Oocyte fertilization was assessed at 18-20 h after insemination by confirmation of the presence and location of two pronuclei.
FF and peripheral blood sample collection FF was obtained within 1 min of ovarian aspiration for IVF. After oocyte retrieval by the embryologist, 1 ml of fluid was collected and mixed with 140 μl of a protease inhibitor mix (10 −5 mol/l phenylmethylsulfonyl fluoride, 10 −5 mol/l pepstatin A, 10 −5 mol/l EDTA, 10 −5 mol/l p-hydroxymercuribenzoate and 9 × 10 −4 mol/l orthophenanthroline; all from Sigma-Aldrich Corp., St. Louis, MO, USA) diluted 50% in 1 ml sterile saline solution. The samples were chilled on ice and centrifuged at 2500g for 10 min at 4°C, and the supernatant was stored at −80°C until peptide extraction and quantification by radioimmunoassay (RIA).
Blood samples were obtained on the day of first gonadotropin prescription and at the time of follicular aspiration. The blood samples for Ang-(1-7) assay were collected in 5 ml EDTA-coated glass tubes, mixed with 0.7 ml of protease inhibitor mix and centrifuged at 2500g for 10 min at 4°C. The plasma was harvested, aliquoted and stored at −80°C. Concomitantly, plasma samples were obtained without adding the protease inhibitor mix and stored at −80°C until assayed for estradiol and progesterone.
Sample extraction and RIA
The FF and plasma samples were thawed and processed for peptide extraction through Bond-Elut cartridges (Analytichem International, Harbor City, CA, USA), then lyophilized on a speed vacuum concentrator, and reconstituted to 65% of the original volume with assay buffer. Ang-(1-7) was quantified in the reconstituted samples by RIA, with a polyclonal antibody produced by Cleveland Clinic Foundation (Cleveland, OH, USA) that exhibits <0.1% cross-reactivity with Ang I, Ang II, Ang-(2-7), Ang-(3-7), Ang-(4-7) and Ang-(1-5), as previously described (Simoes e Silva et al., 2004) .
Steroid hormone assays
Plasma estradiol and progesterone were measured with commercial immunoassays purchased from Roche Diagnostics International Ltd (Rotkreuz, Switzerland) and run in a Cobas 6000 platform with e-601 module (Roche). The assays have lower detection limits of 5 pg/ml and 0.03 ng/ml for estradiol and progesterone, respectively, and their coefficients of variation are <7%.
Granulosa cell isolation and real-time PCR
Luteinized granulosa cells were isolated from follicular aspirates as previously described (Campos et al., 2012) . Briefly, after oocyte retrieval, follicular aspirates of each patient were pooled (aspirates with blood contamination were excluded), washed with phosphate buffered saline (PBS) and centrifuged at 1500 r.p.m. for 10 min. The pellet was resuspended in TCM 199 medium (Sigma-Aldrich, Saint Louis, USA), layered onto Histopaque (Sigma-Aldrich) gradient and centrifuged at 2000 r.p.m. for 20 min. Granulosa cells were recovered from the interface, washed with PBS, and kept frozen until analyzed. This method yields~97% of viable cell recovery with up to 19% of contaminating macrophages (Ferrero et al., 2012) .
RNA was extracted from isolated granulosa cells using phenol-guanidine isothiocyanate (TRIzol; Invitrogen Life Technologies, Carlsbad, CA, USA). Total RNA was extracted and quantified by light absorbance at 260 nm.
First-strand cDNA was synthesized from 1 μg total purified RNA (treated with DNAse I, Invitrogen, Carlsbad, CA, USA) using Superscript first-strand synthesis system (Invitrogen, Carlsbad, CA, USA). Real-time PCR was carried out as described previously (Pereira et al., 2008) in a ABI-Prism 7500 Sequence Detection System, with use of the fluorescent dye Power SYBR Green Master Mix Kit (Invitrogen Life Technologies, Carlsbad, CA, USA). The primer sequences (5′-3′) used for PCR amplification were: ACE2 (Accession number NM_021804.2) CTGCTCATTTGCTTGGTGAT and GGTCCACCATTGCATCAGTA; ACE (NM_000789.3) CACCAC AGAGGCTATGCTA and GCATCGACTTGTTCCAGAACTC; Mas (NM_002377.2) TTCCGGATGAGAAGAAATCC and ATGGCCAGAA GAAAGCTCAT. The gene encoding the ribosomal protein S26 (NM_001029.3) was used as the internal control (Reis et al., 2010) . Primers were designed to span intron-exon borders and thus anneal only to cDNA. The specificity of PCR products was confirmed by single peak dissociation curves and by melting curves. No amplification of fragments occurred in negative control samples prepared without reverse transcriptase. Threshold cycle (CT) values were normalized to S26 (ΔCT) (Livak and Schmittgen, 2001 ).
Protein extraction and dot blotting
Fresh granulosa cells were isolated and suspended in radioimmunoprecipitation assay lysis buffer (50 mmol/l Tris, 150 mmol/l NaCl, 1% Triton-100, 1% deoxycholate, 0.1% sodium dodceyl sulfate, 1 mmol/l phenylmethylsulfonyl fluoride, 10 mmol/l sodium orthovanadate, 10 mmol/l pyrophosphate sodium and 100 mmol/l sodium fluoride) associated with a SigmaFast protease inhibitor tablet (Sigma-Aldrich, Saint Louis, USA, catalog # S8820) followed by sonication on ice at 40% amplitude using five pulses of 5 s on, 10 s off. Protein lysates (75 μl containing 40 μg of total protein) were pipetted on a nitrocellulose membrane which was blocked with 5% skimmed milk in PBS, followed by overnight incubation at 4°C with anti-Mas antibody (rabbit polyclonal supplied by Abcam, Cambridge, UK, catalog # ab66030) diluted 1:250 in PBS containing 0.1% Tween-20. The membrane was washed in PBS-0.1% Tween-20 for three times, incubated for 1 h at room temperature with a horseradish peroxidase-conjugated anti-rabbit (Vector Laboratories, Burlingame, USA) diluted 1:500 in PBS containing 0.1% Tween-20. After new washing, the signal was detected by ultra-sensitive Clarity Western ECL Substrate (Bio Rad, Hercules, USA) and the image was captured by ImageQuant 400 (GE Healthcare, Pittsburgh, USA). Positive and negative controls were incubated with anti-actin primary antibody and non-immune rabbit serum, respectively.
Statistical analysis
Variables were tested for normality with use of D'Agostino-Pearson test. Results from plasma Ang-(1-7) levels before and after ovulation induction and FF Ang-(1-7) levels from the same subjects were compared using Friedman's ANOVA and Dunn's test. The study sample was subdivided according to the FF Ang-(1-7) tertile and the outcomes of the three patient groups (lower, mid and higher tertile of FF Ang-(1-7) concentration) were expressed as medians and interquartile range and compared by Kruskal-Wallis ANOVA and Dunn's test. Simple correlation analyses were performed by calculating the Spearman rank correlation coefficient, whereas a stepwise multiple regression analysis was used to assess which clinical and laboratory variables were independently associated with FF Ang-(1-7) concentration. The analyses were conducted using Graphpad Prism version 6 and IBM SPSS Statistics version 22. Sample size calculations yielded a minimum of 20 subjects per group to detect a difference of at least 20% in the proportion of mature oocytes between groups, with 80% statistical power at 95% significance level. 
Results
The individual plasma concentrations of Ang-(1-7) before and after gonadotropin stimulation are plotted in Fig. 1A and show a consistent, robust elevation after ovulation induction. The median plasma Ang-(1-7) concentration was 41.4 pg/ml (interquartile range 20.1-92.9 pg/ml) at baseline and 160.9 pg/ml (interquartile range 102.4-215.0 pg/ml) after COS (P < 0.0001, Fig. 1B) . The median FF Ang-(1-7) levels were similar to those measured in matching plasma samples (169.9 [129.3-214.0 pg/ml], Fig. 1B ), but there was no linear correlation between plasma and FF Ang-(1-7) levels (r = −0.05, P = 0.665, Fig. 1C ).
Patients at the highest FF Ang-(1-7) tertile had a higher proportion of mature oocytes compared to patients at the lower FF Ang-(1-7) tertile (Table II) . There was a linear correlation between FF Ang-(1-7) and the proportion of mature oocytes (r = 0.380, P < 0.01), which remained significant in the stepwise multiple regression analysis (r = 0.447, P < 0.001) after adjustment for age and duration of infertility and exclusion of other potential confounders such as antral follicle counts and total dose of gonadotropins (Table III) . There were no differences in plasma or FF Ang-(1-7) levels between patients treated with rFSH compared to highly purified urinary gonadotropins or a mixed regimen including both gonadotropin preparations (Supplementary data, Fig. S1 ).
The luteinized granulosa cells expressed mRNA for ACE2 (ΔCT = 0.63), ACE (ΔCT = 1.1) and Mas (ΔCT = 4.5) genes. To further assess the possible role of Ang-(1-7)/Mas receptor pathway on oocyte maturation, we analyzed the correlation between the number of mature oocytes and mRNA expression for Mas in isolated granulosa cells. We found a positive correlation between the number of mature oocytes and Mas expression, which was statistically significant in women with more than three mature oocytes retrieved (r = 0.42, P < 0.01) (Fig. 2) . This association was confirmed in the validation cohort, where Mas mRNA levels correlated with the number of mature oocytes (r = 0.39, P = 0.04, Fig. 2 ). Dot blotting analysis suggested the presence of immunoreactive Mas protein in the granulosa cell lysate (Supplementary data, Fig. S2 ), although specific Mas protein quantification by western blot was not possible due to the limited availability of granulosa cells.
We then correlated Ang-(1-7) levels with ACE2 and ACE gene expression to evaluate the possible contribution of granulosa cells to the production of FF Ang-(1-7), and we did not observe any correlation between ACE2 (r = 0.03) or ACE (r = 0.01) gene expression and FF Ang-(1-7) levels (Fig. 2) .
Discussion
The ovary contains most peptides, receptors and enzymes of the RAS. In rat ovarian follicles, Ang-(1-7) immunoreactivity increases after the endogenous luteinizing hormone peak (Costa et al., 2003) as well as after exogenous gonadotropin injection (Pereira et al., 2009) . Similarly, FF Ang II levels are higher in gonadotropin-stimulated women than in non-stimulated controls (Lightman et al., 1987) . In this study, we used a cohort approach with repeated measures to firstly demonstrate that plasma Ang-(1-7) concentration increases after gonadotropin stimulation in IVF patients. We also identified a high concentration of Ang-(1-7) in ovarian FF, corroborating preliminary cross-sectional observations from our laboratory .
The increase of plasma Ang-(1-7) concentration during COS may be due to ovarian RAS activation, mediated by FSH and/or hCG (Pereira et al., 2009) , followed by peptide diffusion into peripheral plasma. This hypothesis is supported by previous localization of the peptide in rat (Costa et al., 2003; Pereira et al., 2009) and human preovulatory follicles, and by the present demonstration that granulosa cells have mRNAs encoding the enzymes ACE2 and ACE. However, if the ovary were the main source of Ang-(1-7) the peptide concentration would be likely higher in FF than in peripheral plasma, and we found similar Ang-(1-7) levels in both compartments. In addition, there was no correlation between FF and plasma Ang-(1-7) levels, pointing to an extraovarian source contributing to plasma Ang-(1-7) after ovulation induction. The molecular mechanism responsible for systemic RAS activation during COS is unclear. It may involve not only direct gonadotropin stimulation of potential sources but also indirect RAS activation by ovarian peptides or hormones such as estradiol, progesterone or inhibins (Petraglia et al., 1999) .
Ang-(1-7) levels were similar in FF and peripheral plasma obtained simultaneously during oocyte retrieval in gonadotropin-stimulated women, but there was no correlation between FF and plasma concentrations of the peptide. While the similar levels suggest peptide exchange between both compartments, the lack of correlation indicates that no side is the main source of peptide input to the other side. It is unknown whether the same parity of Ang-(1-7) levels in FF and plasma is present during a natural menstrual cycle. It is also uncertain whether gonadotropins promote Ang-(1-7) release by human ovary in vivo, as previously observed in rats (Pereira et al., 2009) . Conclusive evidence for this mechanisms would require collecting FF from the same ovary before and after COS, or from non-stimulated women to serve as a control group, which faces several technical and ethical limitations.
The ovarian RAS can be involved in pathological conditions such as the ovarian hyperstimulation syndrome (OHSS). The increased plasma renin activity in OHSS patients (Navot et al., 1987) suggests that RAS peptides may directly or indirectly promote neovascularization and increased vascular permeability leading to extracellular fluid accumulation, the cornerstones of OHSS (Balasch et al., 1991; Schwentner et al., 2011) . We observed that plasma Ang-(1-7) levels after gonadotropin stimulation were very high, similar to FF levels, suggesting that the systemic vasodilation found during OHSS may be related to Ang-(1-7) effects, and this can be the most important RAS peptide involved in the systemic features of OHSS.
Ang-(1-7) has been shown to induce oocyte maturation process in other species (Honorato-Sampaio et al., 2012) . We corroborate this findings here, as we found a positive correlation between FF Ang-(1-7) levels and the percent of mature oocytes retrieved. That the growing follicle is a target for Ang-(1-7) is suggested by the presence of its specific Mas receptor in several ovarian follicular compartments including the oocyte and by the present evidence of Mas mRNA and protein expression in aspirated granulosa cells. Because our granulosa cell preparation might contain macrophages (Ferrero et al., 2012) , we should also consider ovarian macrophages as putative targets of FF Ang-(1-7). Accordingly, mouse peritoneal macrophages express the Mas receptor and respond to Ang-(1-7) action (Souza and Costa-Neto, 2012) .
Ovulation is a complex process that culminates with follicular rupture and oocyte release, triggered by LH surge in concert with ovarian paracrine mechanisms. However, it remains unclear which paracrine factors are critical and determinant for oocyte maturation and ovulation. Some vascular effects of Ang-(1-7) are mediated by the prostaglandinbradykinin-nitric oxide system (Ferrario, 2006) , which is an important paracrine pathway of ovulation triggering (Polisseni et al., 2005) . However, the study of Ang II/AT2 pathway has produced discrepant findings, since its antagonist saralasin impaired ovulation in rats (Pellicer et al., 1988) , while women with poor ovarian reserve had a negative correlation between AT1 receptor mRNA expression in FF granulosa cells and the number of mature oocytes retrieved (Pena et al., 2010) .
To reconcile these findings, we suggest that both RAS branches have complementary and sometimes counterbalancing roles as intraovarian controllers of follicle rupture and oocyte maturation in mammals.
In conclusion, our data demonstrate substantial plasma Ang-(1-7) increase during COS for IVF. Ang-(1-7) levels may be up-regulated by gonadotropins and this peptide is found in FF, where it is positively associated with the proportion of mature oocytes. Nevertheless, this is an observational study and, therefore, no causal relationship can be established between Ang-(1-7) and human oocyte maturation. Since this peptide promotes oocyte maturation in other species, it deserves further investigation as a potential human oocyte maturation factor. Future studies with systemic administration of Ang-(1-7) may clarify some questions and it is even possible that this peptide may become useful as an adjuvant treatment in IVF patients resistant to gonadotropins. 
